Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Overview
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Companies Involved in Therapeutics Development
Amgen Inc
Arvis Inc
AstraZeneca Plc
Atossa Genetics Inc
Avivia BV
Eagle Pharmaceuticals Inc
Endece LLC
EndoCeutics Inc
Evestra Inc
H3 Biomedicine Inc
Helixmith Co Ltd
Huons Co Ltd
Ji Pharmaceuticals Inc
Novartis AG
Shenogen Pharma?Group Ltd
TTC Oncology LLC
Zenopharm LLC
Zentalis Pharmaceuticals LLC
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Drug Profiles
(bazedoxifene acetate + cholecalciferol) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
acolbifene + prasterone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARV-471 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dehydrodiconiferyl alcohol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EC-372 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Endoxifen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ERX-11 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fosfestrol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fulvestrant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fulvestrant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fulvestrant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
H-3B5942 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
H-3B6545 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
K-07 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Libidua - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Loseasonique - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NDC-1308 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize ESR1 and VEGFR2 for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize ER Alpha for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize ER-Alpha for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize ER-Alpha for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Estrogen Receptor Alpha for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SNG-1153 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SNG-8023 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SR-16234 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TTC-352 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZB-716 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZNc-5 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Dormant Products
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Discontinued Products
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Product Development Milestones
Featured News & Press Releases
Dec 09, 2019: Eagle Pharmaceuticals commences dosing in pilot study for novel estrogen receptor antagonist product candidate
Oct 24, 2019: Arvis reports initial Phase I data for two cancer assets
Oct 17, 2019: Arvis to present initial data from ARV-471 at the 2nd Targeted Protein Degradation Summit
Oct 16, 2019: Atossa Genetics receives IRB approval for phase 2 breast cancer study using intraductal technology
Aug 27, 2019: Arvis announces the initiation of patient dosing in a first-in-human phase 1 study of ARV-471, an estrogen receptor-targeting PROTAC protein degrader
Aug 05, 2019: Eagle Pharmaceuticals announces Clinical Development Plan of innovative product intended to deliver maximum Estrogen Receptor inhibition in patients with Estrogen Receptor (ER)-Positive Breast Cancer
Jun 25, 2019: Arvis receives authorization to proceed for ARV-471, a PROTAC Protein Degrader to treat patients with Locally Advanced or Metastatic ER+ / HER2- Breast Cancer
May 16, 2019: Eisai Presents data on H3B-6545 at 55th ASCO Annual Meeting
Mar 27, 2019: Combo better for HR+ breast cancer patients
Dec 07, 2018: Arvis presents preclinical data on protein degrader, ARV-471, at the 2018 San Antonio Breast Cancer Symposium (SABCS)
Oct 30, 2018: Eagle Pharmaceuticals announces results of study for fulvestrant
Oct 20, 2018: New option for women with advanced breast cancer resistant to hormone therapy
Jul 10, 2018: Cancer Discovery Features H3 Biomedicine Paper Highlighting Effects of Selective Estrogen Receptor Covalent Antagonists (SERCAs) in ERa Wild-Type and Mutant Breast Cancer Models
Jun 01, 2018: ENDECE Attending 2018 Bio Intertiol in Boston
Mar 26, 2018: Mayne Pharma Launches Generic Quartette in the U.S., Another Womens Health Product
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Amgen Inc, H2 2019
Pipeline by Arvinas Inc, H2 2019
Pipeline by AstraZeneca Plc, H2 2019
Pipeline by Atossa Genetics Inc, H2 2019
Pipeline by Avivia BV, H2 2019
Pipeline by Eagle Pharmaceuticals Inc, H2 2019
Pipeline by Endece LLC, H2 2019
Pipeline by EndoCeutics Inc, H2 2019
Pipeline by Evestra Inc, H2 2019
Pipeline by H3 Biomedicine Inc, H2 2019
Pipeline by Helixmith Co Ltd, H2 2019
Pipeline by Huons Co Ltd, H2 2019
Pipeline by Jina Pharmaceuticals Inc, H2 2019
Pipeline by Novartis AG, H2 2019
Pipeline by Shenogen Pharma?Group Ltd, H2 2019
Pipeline by TTC Oncology LLC, H2 2019
Pipeline by Zenopharm LLC, H2 2019
Pipeline by Zentalis Pharmaceuticals LLC, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019